Cholesterol guidelines update: More aggressive therapy for higher-risk patients

Article Type
Changed
Tue, 05/03/2022 - 16:09
Display Headline
Cholesterol guidelines update: More aggressive therapy for higher-risk patients
Article PDF
Author and Disclosure Information

Julie C. Huang, MD
Preventive Cardiology Section, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Byron J. Hoogwerf, MD
Preventive Cardiology Section, Department of Cardiovascular Medicine; Department of Endocrinology, Diabetes, and Metabolism, The Cleveland Clinic Foundation

Address: Julie Huang, MD, Section of Preventive Cardiology, C51, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; email huangj1@ccf.org

Dr. Hoogwerf has indicated that he has received grant or research support from the Amylin and Eli Lilly corporations, serves as a consultant for the Astra Zeneca, Bayer, Eli Lilly, McNeil, Merck, Pfizer, Takeda, and Wyeth corporations, and is on the speaker’s bureaus of the Astra Zeneca, Aventis, Bristol Myers Squibb, Eli Lilly, King, Merck, Monarch, Novo Nordisk, Pfizer, Schering Plough, Takeda, and Wyeth corporations.

Issue
Cleveland Clinic Journal of Medicine - 72(3)
Publications
Topics
Page Number
253-262
Sections
Author and Disclosure Information

Julie C. Huang, MD
Preventive Cardiology Section, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Byron J. Hoogwerf, MD
Preventive Cardiology Section, Department of Cardiovascular Medicine; Department of Endocrinology, Diabetes, and Metabolism, The Cleveland Clinic Foundation

Address: Julie Huang, MD, Section of Preventive Cardiology, C51, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; email huangj1@ccf.org

Dr. Hoogwerf has indicated that he has received grant or research support from the Amylin and Eli Lilly corporations, serves as a consultant for the Astra Zeneca, Bayer, Eli Lilly, McNeil, Merck, Pfizer, Takeda, and Wyeth corporations, and is on the speaker’s bureaus of the Astra Zeneca, Aventis, Bristol Myers Squibb, Eli Lilly, King, Merck, Monarch, Novo Nordisk, Pfizer, Schering Plough, Takeda, and Wyeth corporations.

Author and Disclosure Information

Julie C. Huang, MD
Preventive Cardiology Section, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Byron J. Hoogwerf, MD
Preventive Cardiology Section, Department of Cardiovascular Medicine; Department of Endocrinology, Diabetes, and Metabolism, The Cleveland Clinic Foundation

Address: Julie Huang, MD, Section of Preventive Cardiology, C51, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; email huangj1@ccf.org

Dr. Hoogwerf has indicated that he has received grant or research support from the Amylin and Eli Lilly corporations, serves as a consultant for the Astra Zeneca, Bayer, Eli Lilly, McNeil, Merck, Pfizer, Takeda, and Wyeth corporations, and is on the speaker’s bureaus of the Astra Zeneca, Aventis, Bristol Myers Squibb, Eli Lilly, King, Merck, Monarch, Novo Nordisk, Pfizer, Schering Plough, Takeda, and Wyeth corporations.

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 72(3)
Issue
Cleveland Clinic Journal of Medicine - 72(3)
Page Number
253-262
Page Number
253-262
Publications
Publications
Topics
Article Type
Display Headline
Cholesterol guidelines update: More aggressive therapy for higher-risk patients
Display Headline
Cholesterol guidelines update: More aggressive therapy for higher-risk patients
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media